Supersedes: This is a new CPG and must be reviewed in its entirety.
Goal.
To provide guidance on the recognition and comprehensive management of invasive fungal infection (IFI) in war wounds.
Background.
a. Clinically significant infections, to include fungal wound infections, have occurred in our wounded warrior population since the beginning of the current conflicts. However, in the setting of increasing severe and frequent Improvised Explosive Device blast injuries, there has been a corresponding increase in the incidence of fungal wound infections. Of concern is an apparent recent increase in angioinvasive Mucor and Aspergillus terreus in this patient population. These are devastating infections once the fungi (which are typically opportunistic pathogens) gain a foothold. These fungal infections have led to increased mortality, morbidity, and in some cases prolonged hospitalization for survivors.
b. DoD review of IFI cases 3 demonstrated that the most common clinical findings associated with IFI included dismounted blast injury, above knee traumatic amputations, and extensive perineal/pelvic injury, frequently requiring massive blood transfusion (often ≥ 25 units in the first 24 hours). The majority of these cases have occurred following injury in the Helmand or Kandahar provinces in southern Afghanistan.
c. Prevention strategies have not been clearly identified, but early and aggressive debridement of devitalized tissue and removal of debris are universally accepted as the most important factors. The role of topical antifungal therapy in the prevention of IFI is not clear.
d. The treatment of IFI is based on three main principles: debridement of infected tissue, minimization of immunosuppression (e.g. malnutrition, excessive blood transfusion), and utilization of systemic anti-mold medications.
e. The morbidity associated with IFI in the severe war wounds, which includes tissue loss, has led to a renewed interest in early treatment of patients identified as high risk. The outcome using this earlier treatment is being monitored closely.
Evaluation and Treatment.
a. The most important aspect of evaluation and treatment of war wounds is early, aggressive, and frequent surgical debridement of all devitalized tissue and organic material.
b. After initial debridement, risk factors for invasive fungal infection will be assessed. Identified risk factors include:
November 2012 e. For patients transferred to Bagram (or any Level III/Role 3 strategic evacuation hub), risk factors for IFI will be assessed and ongoing resuscitation requirements will be addressed. The patient should undergo debridement and wound washout within 12 hours of arrival. Dakins wound irrigations and topical antifungal dressings as described above will be initiated/continued.
f. Topical anti-fungal treatment using 0.0025% Dakins solution via instillation vacuum dressing will be continued throughout the evacuation phase. Flight teams will receive instruction on management of the instillation prior to leaving the MTF. In the event of malfunction during flight, the instillation may be held while vacuum dressing is continued. The trauma surgeon on call will be then be contacted to evaluate the dressing immediately on arrival to the next level of care.
g. On arrival to the Level IV MTF, the patient will undergo debridement and wound washout within 18 hours. Histopathology and microbiology specimens will be obtained at Level IV on all patients with at least three risk factors for IFI. Continue topical antifungal therapy with 0.0025% Dakins solution using an instillation vacuum dressing or 0.0025% Dakins soaked kerlix if there is continued suspicion or three risk factors for invasive fungal infection.
h. On arrival to the Level V MTF, the patient will undergo debridement and washout within 18 hours. Histopathology and microbiology specimens will be obtained at Level V on all patients with at least three risk factors for IFI who have poor wound appearance, tissue necrosis or compromise. ii. Patient's name, DOB, and hospital identification number c) Directly contact the histology lab during working hours and the on-call pathologist after hours and on weekends.
3) The histopathology specimen must leave the OR as a fresh specimen.
4) Call the Pathology Lab to let them know they will receive a histopathology specimen shortly and deliver the histopathology specimen to the Pathology Lab as soon as possible.
5) Pathology staff will coordinate processing as rapidly as possible (≤ 48 hours) a) Histological specimen will be stained with H&E and GMS stains, and evaluated for fungal organisms.
b) Microbiological specimen will be cultured for aerobes, anaerobes, and fungi. c) Mycobacterial cultures will not be done routinely under this protocol, but may be done with special request.
o. If angioinvasive fungal elements or fungal elements among necrotic debris are reported on histopathology, or if cultures are positive in the setting of recurring necrosis, begin treatment with systemic antifungal medications. Treatment will require close consultation with Infectious Disease; however, as a general guideline, stop systemic antifungal medications after 2 weeks if the patient remains clinically stable and the wounds remain clean/viable. If the patient has fungal infection in more than one body region-e.g., extremity/pelvis and abdomen, chest, etc., long term treatment may be indicated.
NOTE:
1) Fungal cultures can take up to 6 weeks to grow. It is therefore recommended that the cultures be checked frequently for 2 weeks; then once a week for 4 more weeks before they are considered final.
2) Initial studies have shown that combat IFI wound cultures growing Mucor will have a second non-Mucor fungus present 30% of the time. Aspergillus Terreus is more difficult to grow than mucor. Therefore, dual use of Voriconazole and Liposomal Amphotericin B is suggested for wounds infected with either or both of these fungi. If long term treatment is required, the antifungal medications may be focused based on culture results.
p. Aggressive surgical debridement of all necrotic and infected tissue remains the mainstay of treatment for invasive fungal infection. Debridements should continue at least every 24 hours until further debridement is not required. Wound coverage and closure should not occur until after the wound is clean, contracting, and granulating.
Performance Improvement (PI) Monitoring.
Correct identification and documentation by the trauma team of patients at increased risk for IFI (≥ 3 risk factors).
Debridement within 18 hours of arrival at each facility for patients at increased risk for IFI (≥ 3 risk factors).
Appropriate biopsy including site & specimen selection, specimen handling, and notification of the pathology department.
Topical Dakins dressing initiated in theater in patients at increased risk for IFI (≥ 3 risk factors). Appropriate documentation of wound appearance at each level of care using standardized op note for patients at increase risk for IFI (≥ 3 risk factors). Antifungal medications started when there is significant progressive tissue necrosis on two consecutive debridements, not including the first two debridements.
Systemic and topical antifungal treatments stopped when no evidence of IFI on histology or culture.
a. Intent (Expected Outcomes).
1) Casualties at risk for invasive fungal infections will be identified early along continuum of care.
2) Documentation with specific attention to risk factors for invasive fungal infection will be performed at each level of care.
b. Performance/Adherence Measures.
1) Casualties with three or greater of invasive fungal risk factors are taken to OR within 12 hours upon arrival at Level III or Level IV MTFs.
2) Casualties with three or greater of invasive fungal risk factors have Dakin's solution applied to wounds.
3) Standardized op note will be used at Level III facilities in theater and Level IV facilities for casualties with two or greater risk factors for invasive fungal infection.
c. Data Source. The above constitutes the minimum criteria for PI monitoring of this CPG. System reporting will be performed annually; additional PI monitoring and system reporting may be performed as needed.
